Soy, isoflavone consumption not associated with endometrial cancer risk
the ONA take:
According to a new study published in the journal BJOG, an international journal obstetrics and gynecology, researchers from the National Cancer Center in Tokyo, Japan, have found that soy food/isoflavone consumption is not associated with endometrial cancer risk in Japanese women.
For the study, researchers sought to investigate whether a correlation exists between soy food/isoflavone consumption and endometrial cancer risk because consumption of soy food in Japan is very high while endometrial cancer incidence is very low.
Researchers conducted a prospective cohort study that included 49,121 Japanese women aged 45 to 74 years. Participants completed self-administered food frequency questionnaires that assessed intake of soy foods and isoflavones between 1995 and 1998, followed by a 5-year follow-up survey.
Results showed that during an average follow-up of 12.1 years, there were 112 cases of newly diagnosed endometrial cancer. The researchers found no association between soy food and isoflavone consumption and endometrial cancer risk.
Soy food/isoflavone consumption is not associated with endometrial cancer risk in Japanese women.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|